Latest news with #WorldCongress
Yahoo
4 days ago
- Business
- Yahoo
Qbtech Expands US Presence with Formation of New Houston-Based Teams and Staff Appointments
Addition of clinical research and strategic partnership teams marks another milestone for Qbtech in North America, bolstering the company's regional capabilities and footprint HOUSTON, June 02, 2025--(BUSINESS WIRE)--Qbtech, the global leader in objective ADHD testing, announces the formation of its Houston-based clinical research and strategic partnership teams, along with new staff appointments and promotions at the company's US headquarters. The employee expansions bolster the company's continued growth in the region, enhancing its capabilities and market presence as it continues to develop and enhance its software solutions. Former clinical research manager Ragini Sanyal has been promoted to Head of Clinical Research, with Jonas Bäckström joining as Chief Strategic Partnership Officer and Jack Smith as Head of US Commercial Operations. As Head of Clinical Research, Sanyal will lead the formalized clinical research team and its efforts to study the clinical utility and validity of objective ADHD assessments for diagnosing ADHD and its benefits in post-treatment follow-up. "I truly believe objective ADHD technology is a guiding light through the uncertainty of the mental health space. I'm so excited to take on this role and lead our newly structured clinical research team to curate and share the data behind our objective assessments and how they can be used to progress ADHD care," says Sanyal. "This new team structure allows us to streamline our efforts across clinical operations, data management, medical writing, and trial execution. It will also help simplify decision-making, improve cross-functional collaboration, and provide a clearer focus as we continue to expand both our team and our portfolio. Coming off the World Congress on ADHD, I am so proud that our team was able to present four meaningful posters, and I can only imagine what we will accomplish in the coming months and years." Jonas Bäckström, a former member of Qbtech's Board of Directors, has joined as Chief Strategic Partnership Officer, leading the newly established partnerships department from the Houston office. He brings a strong background in digital innovation, having worked with a pioneering digital healthcare provider in Sweden prior to joining Qbtech. "This is an exciting opportunity for both me and Qbtech," says Bäckström. "I look forward to focusing on building scalable, evidence-based business models in the ADHD space and linking telehealth innovation with clinical, payer, and employer ecosystems. With my experience in business development and digital health, I am eager to help our partners achieve sustainable growth, improve patient outcomes, and shape a smarter, more accountable future for mental health, starting with ADHD." Jack Smith will serve as Head of US Commercial Operations, leading efforts across sales and clinical support to drive Qbtech's expansion and identify new growth opportunities. A military veteran, Smith has served in various roles within the healthcare industry for more than 25 years. "I'm thrilled to be joining Qbtech at such a pivotal time in the US ADHD market. My goal is to build a world-class sales team that delivers real value to clinicians by driving improved patient outcomes through objective, evidence-based tools," says Smith. "As awareness grows and underserved markets expand, we have a unique opportunity to empower physicians with the confidence they need to make accurate ADHD diagnoses." The Qbtech team plans to hire additional staff in the Houston office throughout the year. Available career opportunities can be found at About Qbtech Founded in 2002, Qbtech is a privately-owned Swedish company that has developed leading solutions and products for improving the identification, diagnosis, treatment, and follow-up of patients living with ADHD. Qbtech has operations in 14 countries and has offices in Stockholm, Houston, and London. Qbtech is an award-winning company recognized for its innovation, most recently winning the 2022 HSJ Partnership Award for the 'Best Mental Health Partnership with the NHS.' For more information about Qbtech, visit View source version on Contacts Media Contact: Hilari Barton, Trevelino/KellerHnbarton@ 404-214-0722 x 130
News.com.au
26-05-2025
- Business
- News.com.au
Health Check: The endo-metriosis? Proteomics is on the case
Having produced more positive diagnostics results, Proteomics plans to launch its Promarker Endo device locally this year Immutep posts more positive trial results, this time for soft tissue sarcoma Broker values EBR Systems share price at more than double current worth after capital raising Proteomics International Laboratories (ASX:PIQ) has come up with more positive data to support its endometriosis diagnosis test Promarker Endo, presented – aptly – to the World Congress on Endometriosis, held in Sydney over the weekend. Affecting one in nine women and girls, endometriosis is a common and painful disease that occurs when tissue similar to the lining of the uterus grows in other parts of the body. The condition takes on average seven years to diagnose, owing to the need for an invasive laparoscopy followed by histopathology (a camera is inserted into the pelvis through a small cut in the abdominal wall). The condition is often misdiagnosed. Promarker Endo is a non-invasive alternative, providing a 'traffic light' risk score of low, moderate to high. Derived from analysing 704 plasma samples, the latest results follow those of a 'breakthrough' study of 805 samples in December last year. The latest results showed an 83-98% ability to detect the disease and a 95% ability to rule it out. The company says the results shows that Promarker Endo 'demonstrates high diagnostic accuracy across all stages of endometriosis using a single universal test.' The company plans to launch Promarker Endo locally, in the September quarter. Immutep reports more promising cancer trial results When it comes to its lead compound dubbed 'efti', immuno-oncology drug developer Immutep (ASX:IMM) can't be accused of depriving investors of news flow. Immutep shares surged up to 11% after the company reported 'remarkable' patient response rates in a German lung cancer trial. Today, the company said a phase II soft tissue sarcoma trial hit its primary endpoint, when combining efti with radiotherapy and the standard of care checkpoint inhibitor, Keytruda. A rare cancer, soft tissue sarcoma starts in the soft tissues of the body, including muscle, fat, nerves, blood vessels, and tendons. The investigator-led trial exceeded the study's prespecified median of 35% tumour hyalinisation/fibrosis, versus 15% for historical data from radiotherapy alone in patients with resectable (operable) soft tissue sarcoma. Tumour hyalinisation/fibrosis is an early surrogate endpoint at the time of surgical resection that has been associated with improved overall survival and recurrence-free survival. Hyalinisation is a process where normal tissue degenerates into a translucent material called hyaline. So, while hyalinsation/fibrosis seems like a 'bad' thing, the presence of it leads to a heightened anti-cancer response. Enrolling 40 patients in January this year, the investigator-led trial was carried out at Warsaw's Maria SkÅ‚odowska-Curie National Research Institute of Oncology. Immutep is also trialling efti, a so-called Lag-3 protein, for other solid tumours including non-small cell lung cancer, head and neck squamous cell carcinoma and metastatic breast cancer. EBR shares find their groove Fresh from EBR Systems' (ASX:EBR) $56 million capital raising last week, broker Canaccord values the company's stock at $2.50 per share, more than double their current worth. By way of a placement, EBR's whip-'round was carried out to fund the US commercialisation of its Wise left-ventricle pacemaker, which the US Food & Drug Administration (FDA) approved in mid-April. Now comes the equally hard part of convincing surgeons and obtaining reimbursement. On the latter, Canaccord says EBR is on track to obtain full reimbursement by October 1, for both inpatients and outpatients. The firm believes some surgeons and hospitals won't wait until then, with the first procedures likely in early August. 'Recent clinician discussions have suggested US hospitals are willing to absorb the cost of Wise pre reimbursement, for patients with a lack of alternative solutions.' In other words: 'if you can't pay, don't worry – we will spot you'. While the initial implants are likely to amount to only a handful, they will show the 'excitement about Wise among clinicians and patients'. Announced last Thursday, the placement was executed at $1 a share, a circa 18% discount on the frozen price of $1.215. The stock initially was sold down to $1.06 but is now trading above the pre-placement price. The shares were sold off sharply post FDA approval, partly reflecting expectations of a capital raise. EBR has US$84 million in the bank, but Canaccord's valuation assumes the issuance of a further 105 million shares in a follow-on raising, in 2025-26 or 2026-27. Medical devices 'safe haven' Canaccord notes that medical device makers generally have proved a haven in the US market turmoil, outperforming both the healthcare index and the S&P 500 index. US-listed device makers have gained 7.7% since the start of the year, compared with a 1.4% gain for the S&P 500 and a 3.3% decline for the proxy index, the Ishares US medical device ETF. ASX device makers have enjoyed a purple patch, with the FDA approving Orthocell's (ASX:OCC) Remplir nerve regeneration device in early April. In March the agency green-lit Nanosonics' (ASX:NAN) next-gen medical probe steriliser, Coris and Artrya's (ASX:AYA) AI-enabled coronary plaque detection tool. Medical devices don't tend to offer the same upside as an approved drug, but they are far less risky proposition. While-no one quite knows what's going on in the mind of Donald Trump, they are not in the firing line in the same way as overseas (notably European) drug makers. Rhythm nails it with 'poo test' alternative There's more on the diagnostics front, with Rhythm Biosciences (ASX:RHY) completing testing the second stage of testing of Colostat, its blood-based test for bowel cancer. Using banked patient samples, the second-generation (beta) kit generated around 23,000 data points 'to evaluate a variety of variables including inter and intraplate precision, interference and detection limits'. More than 96% of the total tests 'comfortably met the performance targets for their operational use.' The remaining 4% will be 'compensated for' in the final, manufactured product. In short, the test meets the 'performance required to meet or exceed the proposed clinical use as a triage test for patients symptomatic for bowel disease'. The next step involves Rhythm's partner Quansys producing pilot kits, followed by final testing with independent clinical samples. 'Following completion of the above, Rhythm will be able to make Colostat commercially available through Rhythm's commercial laboratory.' This would be by way of National Association of Testing Authorities verification, or through partner laboratories using their own accreditation. Ultimately, the assay aims to replace the current 'poo test', which many users find cumbersome, abhorrent for cultural reasons or simply unattractive.
Yahoo
23-05-2025
- Business
- Yahoo
Moldova to Host the 46th World Congress of Vine and Wine - in the Country with the Highest Vineyard Density per Capita
What You Should Know About This Wine Nation CHIȘINĂU, Moldova, May 23, 2025 /PRNewswire/ -- This year, the World Congress of Vine and Wine will take place for the first time in the Republic of Moldova – the country with the highest vineyard area per capita in the world, with 4 hectares for every 100 people. Moldova's total vineyard area reaches nearly 110,000 hectares. The country ranks among the top 20 wine producers globally and is the 14th largest wine exporter in the world. In 2024, Moldova exported 144 million liters of wine, worth over 234 million USD. Moldovan wines are shipped to 73 countries, with half of all exports going to European markets. In Moldova, wine is not just an industry – it is part of the country's identity, history, and economy. Over the past few years, the wine sector has grown significantly, thanks to high quality and improved wine tourism infrastructure. Moldova now has over 250 wineries, offering great wines and unforgettable experiences for visitors from around the world. Moldova has built a strong reputation in the international wine world not only through its authentic terroir and ancient traditions, but also through the growing recognition it has earned in recent decades. In the past five years, Moldovan wines have won thousands of medals at top global competitions – including Berliner Wine Trophy, Mundus Vini, Decanter World Wine Awards, and Concours Mondial de Bruxelles. These awards have helped Moldova become known as a serious producer of high-quality wines, able to compete internationally and impress even the most demanding wine experts. A major milestone in promoting Moldovan wines abroad was the creation of the National Office of Vine and Wine (ONVV) and the launch of the national brand "Wine of Moldova: Unexpectedly Great" in 2013. The 46th edition of the World Congress of Vine and Wine will take place from June 16 to 20, 2025, at the Palace of the Republic in Chișinău, Moldova. The congress will bring together 300 experts, researchers, winemakers, oenologists, producers, and policymakers from 51 member countries of the OIV, to discuss the future of the global wine industry. Participants will also take part in 13 technical visits to Moldova's most renowned wineries, and enjoy a festive dinner hosted at Cricova – the world-famous underground wine city known for its vast tunnels and excellent wines. Participation packages are available for purchase on the official congress website: The event is organized by the International Organisation of Vine and Wine (OIV), in collaboration with the Ministry of Agriculture and Food Industry of Moldova and the National Office for Vine and Wine (ONVV). Moldova has been a member of the OIV since April 3, 2001 – the first country from the CIS to join the organization. In 2024, the OIV celebrates its 100th anniversary, and the congress in Moldova marks the beginning of its second centenary. Photo: View original content to download multimedia: SOURCE World Congress of Vine and Wine Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10-05-2025
- Health
- Yahoo
New Study from UK's Largest Virtual ADHD Service Validates Role of Objective Testing in Delivering Personalized, High-Quality Remote ADHD Care
Data presented at ADHD World Congress highlights how QbCheck supports diagnostic accuracy and individualized treatment monitoring, enabling efficient and robust care in virtual settings. News Summary: New findings show significant improvements in access, clinician confidence, symptom tracking, and individualized care using objective testing. The study underscores the importance of scalable, evidence-based tools, as many countries, including both the UK and the US, face rising demand for ADHD diagnosis and treatment. The study revealed significant improvements post-treatment, validating clinical practice and better clinician-patient alignment. LONDON & PRAGUE, May 10, 2025--(BUSINESS WIRE)--As demand for virtual ADHD care increases, findings from a new study conducted with ADHD 360, the UK's largest evidence-based digital service specializing in ADHD diagnosis and treatment, reveal how objective ADHD diagnostic and monitoring technology improves patient outcomes and clinical certainty. Presented at the 2025 ADHD World Congress in Prague, Czech Republic, the findings highlight the role of QbCheck, Qbtech's remote testing solution, in enabling clinicians to make more confident, data-informed decisions, supporting a more personalized and collaborative care model. The tool allows for greater clarity when assessing symptoms and adjusting treatment plans over time, ensuring diagnostic accuracy and helping to improve alignment between clinicians and patients throughout the care journey. The results from ADHD 360's implementation of this model showcase how a standardized approach to virtual ADHD care improves clinician confidence, reduces wait times, and enhances patient engagement. In addition to its use as a diagnostic tool, QbCheck, the remote objective assessment tool from Qbtech, was used to monitor treatment effects, helping clinicians adjust treatment as needed. "Consistency and quality are at the heart of our virtual care model, and QbCheck plays a key role in upholding these standards," says Carl Ellis, Mental Health Nurse and Team Manager, ADHD 360. "The objective data it provides ensures that every patient is assessed using the same evidence-based criteria, regardless of where they are. Not only does this minimize the risk of subjective bias, but it also ensures that our clinical team can deliver reliable, high-quality care at scale." The results showed significant improvement from the baseline to post-treatment assessments. Beyond QbCheck's value as an objective symptom measurement and diagnostic tool, the data highlights patient response to pharmacological treatment, which can support clinicians in developing individualized and adaptive treatment plans, providing quantifiable data on symptom presentation and response. In this study, data was collected from routine QbCheck assessments completed as part of the ADHD 360 model in the United Kingdom. Baseline data was collected prior to diagnosis and treatment, with additional QbCheck assessments administered after patients were optimized with stimulant medication treatment. In addition to QbCheck, all patients were given the Adult ADHD Self Report Scale (ASRS) or the Swanson, Nolan and Pelham Rating Scale (SNAP) and QbCheck Rating Scale (QbRS) to assess self-reported symptoms. "QbCheck brings transparency and structure to the process, enabling clinicians to clearly visualize symptoms, track treatment response, and give patients the objective validation they deserve," says Dr. Mikkel Hansen, Chief Medical Officer, Qbtech. "This data shows how a standardized pathway to virtual ADHD care helps clinicians successfully facilitate remote monitoring of medication treatment effects, symptom regulation, and overall treatment outcomes, which are essential to virtual care models like ADHD 360." With increased scrutiny around ADHD care and virtual care models expanding, QbCheck stands out for its clinical rigor, patient-centered design and scalability. First developed in 2016, QbCheck enriches the clinician and patient experience to ensure optimal care in virtual settings. QbCheck is used by more than 10,000 clinicians worldwide operating virtual clinics and those with brick-and-mortar locations who offer remote ADHD services. Its flexibility for these clinicians and their patients is key to providing equitable access to care regardless of location, especially those who live in a mental health provider shortage area. Since its launch in Sweden in 2002, Qbtech has supported more than 1 million patients globally. More than 40 independent studies document the company's benefits across the patient care pathway, including improved access to care, elevated clinician confidence, a 50% better indication of treatment effects than standardized self-rating scales, and consistency of care across multiple disciplines. Visit to learn more. About Qbtech Founded in 2002, Qbtech is a privately-owned Swedish company that has developed leading solutions and products for improving the identification, diagnosis, treatment, and follow-up of patients living with ADHD. Qbtech has operations in 14 countries and has offices in Stockholm, Houston, and London. Qbtech is an award-winning company recognized for its innovation, most recently winning the 2022 HSJ Partnership Award for the 'Best Mental Health Partnership with the NHS.' For more information about Qbtech, visit View source version on Contacts Media Contact: Hilari Barton, Trevelino/KellerHnbarton@ 404-214-0722 x 130
Hi Dubai
17-03-2025
- Sport
- Hi Dubai
UAE to Host Global Rowing Events as World Rowing Federation Expands Agenda
The World Rowing Federation has unveiled plans to organise international rowing events in the UAE, reinforcing its status as a premier sports hub, particularly for water and marine sports. The decision underscores the country's advanced infrastructure and conducive environment for hosting world-class sporting events. Jean-Christophe Rolland, President of the World Rowing Federation, emphasized that the UAE's facilities and commitment to sporting excellence make it an ideal destination for global competitions. The federation's agenda for 2027 and 2028 includes Olympic rowing, coastal rowing, beach sprint rowing, virtual rowing, and indoor rowing, expanding the scope of the sport in the region. These announcements came as the UAE Sailing and Rowing Federation participated in the 2025 World Congress meetings held in Lausanne, Switzerland, where representatives from 160 national federations convened. With this initiative, the UAE further strengthens its position as a global sporting powerhouse, set to welcome elite rowing talent in the coming years. News Source: Emirates News Agency
